hotspot -WSS

hotspot

author：leisure time 2025-10-01 17:33:31 - browse：4

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Hospital chaplains balance Covid safety with patients’ spiritual needs

knowledge

WSS

New Covid vaccine is recommended for everyone 6 months or older

Medicare Advantage coverage denials need scrutiny, senators say

Merck to acquire Harpoon Therapeutics for $680 million

PEPFAR is under serious threat — and so is global health

Will the IRA bring competition to the biologics market?

American taxpayers paid $1.8 trillion in health care costs in 2022

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Jerome Adams on the need for new antivirals for Covid

How to make the FDA’s new prescription one

Walensky prepares to leave CDC — and Congress — behind

Diverse clinical trials: Why aren’t we there yet?

Medical leaders decry Supreme Court decision on affirmative action

Pig kidney works a record two months in donated body

United colonoscopy coverage change 'may cost lives,' doctors say

Boston Scientific acquires urology company Axonics for $3.7 billion

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA approves updated Covid vaccines

knowledge

Private equity could exacerbate cardiology's overuse problem, experts fear

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Nonprofit, backed by Microsoft, to certify AI tools in health care

Diverse clinical trials: Why aren’t we there yet?

PEPFAR is under serious threat — and so is global health

Nonprofit, backed by Microsoft, to certify AI tools in health care

entertainment

knowledge

leisure time

hotspot